Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
VALN · against 466 other Healthcare companies of similar size
Ranked #301 of 467 · scores higher than 13% of peers
Bars: peers in each 10-point band of the valuation score167 peers with a valuation score of 0–9, including VALN · Click a bar to see the companies
Mainly because of its earnings yield, EBITDA yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | VALN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 454 reported | Not reported | 0.5% | — | — | 30% |
| EBITDA yieldHigher is better · 472 reported | -18.0% | 3.4% | 14% | 50% | |
| Free cash flow yieldHigher is better · 201 reported | -12.6% | -6.5% | 35% | 20% | |
| Book yieldHigher is better · 462 reported | 23.0% | 47.7% | 21% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 301 | 371M USD | 8 | ||
| 301 | 394M USD | 8 | 37 | |
| 301 | 513M USD | 8 | 31 | |
| 301 | 289M USD | 8 | ||
| 301 | 522M USD | 8 | 12 | |
| 301 | 885M USD | 8 | 33 | |
| 301 | 595M USD | 8 | 29 | |
| 301 | 705M USD | 8 | 32 | |
| 301 | 453M USD | 8 | 6 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score